Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia

Antony D Loebel, Cynthia O Siu, Josephine B Cucchiaro, Andrei A Pikalov, Philip D Harvey, Antony D Loebel, Cynthia O Siu, Josephine B Cucchiaro, Andrei A Pikalov, Philip D Harvey

Abstract

Objective: The aim of this analysis was to compare the effects of 2 atypical antipsychotic agents, lurasidone (80 mg/d or 160 mg/d) and quetiapine XR (600 mg/d), on daytime alertness, and to evaluate the effects of daytime sleepiness on treatment outcomes in patients with an acute exacerbation of schizophrenia.

Methods: Patients who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) criteria for schizophrenia were randomized to 6 weeks of double-blind treatment with fixed doses of lurasidone 80 mg/d (n = 125), lurasidone 160 mg/d (n = 121), quetiapine XR 600 mg/d (n = 119), or placebo (n = 121), all dosed once daily in the evening, with food. Daytime sleepiness was assessed using the Epworth Sleepiness Scale (ESS).

Results: Daytime sleepiness improved in the lurasidone and placebo-treated groups but worsened in the quetiapine XR treatment group when compared to placebo (p = 0.001) and to either dose of lurasidone (both p < 0.01). Sedation associated with quetiapine XR treatment mediated an improvement in agitation [assessed by the Positive and Negative Syndrome Scale-Excitement (PANSS-EC) subscale] and a worsening in functional capacity [assessed by the University of California-San Diego (UCSD) Performance-Based Skills Assessment-Brief Version (UPSA-B) total score]; these mediating relationships were not observed for the lurasidone or placebo treatment groups.

Conclusion: In this 6-week double-blind study, treatment with lurasidone 80 mg or 160 mg, administered once daily in the evening, was associated with a reduction in daytime sleepiness similar in magnitude to placebo, while quetiapine XR 600 mg/d was associated with a significant increase in daytime sleepiness, compared to both lurasidone dose groups and placebo. Daytime sleepiness was associated with improvement in agitation and worsening in functional capacity for quetiapine XR, but not lurasidone or placebo-treated patients.

Figures

Figure 1
Figure 1
Change from baseline in Epworth Sleepiness Scale.
Figure 2
Figure 2
Change from baseline in Epworth Sleepiness Scale: Item analysis.
Figure 3
Figure 3
Change in sleepiness as a mediator of change in PANSS excitement subscale: Mediation regression analysis.
Figure 4
Figure 4
Change in sleepiness ESS item ‘dozing while talking’ and change composite Z score: Mediation regression analysis.
Figure 5
Figure 5
Change in sleepiness and change in UPSA-B performance score: mediation regression analysis.

References

    1. Kane JM, Sharif ZA Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry. 2008; 69(Suppl 1): 18–31
    1. Hawley CJ, Gale TM, Sivakumaran T, et al. Excessive daytime sleepiness in psychiatric disorders: prevalence, correlates and clinical significance. Psychiatry Res. 2010; 175(1–2): 138–141
    1. American Academy of Sleep Medicine (AASM) Driving Fact Sheet, December 2, 2009. Accessed July 26, 2012.
    1. Colten HR, Altevogt BM, eds. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Washington, DC: National Academy of Sciences. Accessed July 16, 2012.
    1. Harvey PD, Hassman H, Mao L, et al. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar 1 disorder: a randomized, double-blind, crossover study. J Clin Psychiatry. 2007; 68(8): 1186–1194
    1. Johns MA A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991; 14(6): 540–545
    1. Johns MW Epworth Sleepiness Scale (ESS) In Rush Jr AJ, First MB, Blacker D, Eds. Handbook of Psychiatric Measures, 2nd ed.Washington, DC: American Psychiatric Publishing; 2008
    1. Fleischhacker WW, Heikkinen ME, Olié JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010; 13(8): 1115–1125
    1. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophrenia Res. 2013; 145(1–3): 101–109
    1. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structural diagnostic psychiatric interview for DSM-IV and ICD-10 1996. J Clin Psychiatry. 1998; 59(Suppl 20): 22–23
    1. Baldwin CM, Scott LJ Quetiapine extended release: in schizophrenia. CNS Drugs. 2009; 23(3): 261–269
    1. Zhornitsky S, Potkin S, Moteshafi H, et al. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol. 2011; 26(4): 183–189
    1. Chervin RD The multiple sleep latency test and Epworth Sleepiness Scale in the assessment of daytime sleepiness. J Sleep Res. 2000; 9(4): 397–400
    1. Lohr JB, Liu L, Caligiuri MP, et al. Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2013; 150: 289–296
    1. Kay SR, Fiszbein A, Opler LA The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261–276
    1. Lindenmayer JP, Brown E, Baker RW, et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophrenia Res. 2004; 68(2–3): 331–337
    1. Pietrzak RH, Olver J, Norman T, et al. A comparison of the CogState schizophrenia battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol. 2009; 31(7): 848–859
    1. Mausbach BT, Harvey PD, Goldman SR, et al. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr Bull. 2007; 33(6): 1364–1372
    1. Mackinnon DP, Fairchild AJ, Matthew SF Mediation analysis. Annu Rev Psychol. 2007; 58: 593–614
    1. Kraemer HC, Wilson GT, Fairburn CG, et al. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002; 59(10): 877–883
    1. Harvey PD, Velligan DI International assessment of functional skills in people with schizophrenia: innovations in clinical neuroscience. Innov Clin Neurosci. 2011; 8(1): 15–18
    1. Harvey PD, Siu CO, Hsu J, et al. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013; 23(11): 1373–1382
    1. Riesenberg RA, Baldytcheva I, Datto C Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-released during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study. Clin Ther. 2012; 34(11): 2202–2211
    1. Witek TJ Jr, Canestrari DA, Miller RD, et al. Characterization of daytime sleepiness and psychomotor performance following H1 receptor antagonists. Ann Allergy Asthma Immunol. 1995; 74(5): 419–426
    1. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-HT7 and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334(1): 171–181
    1. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951–962
    1. Horiguchi M, Huang M, Meltzer HY The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther. 2011; 338(2): 605–614
    1. Guilleminault C, Brooks SN Excessive daytime sleepiness: a challenge for the practising neurologist. Brain. 2001; 124(Pt 8): 1482–1491
    1. Rosenheck RA Effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anti-cholinergics as a comparator. Psychiatr Serv. 2005; 56(1): 85–92
    1. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373(9657): 31–41

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa